Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

99.57USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$99.57
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,987,861
52-wk High
$125.84
52-wk Low
$69.40

Chart for

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $144,249.59
Shares Outstanding(Mil.): 1,594.09
Dividend: 0.64
Yield (%): 2.83

Financials

  ABBV.N Industry Sector
P/E (TTM): 22.10 30.95 32.75
EPS (TTM): 4.09 -- --
ROI: 11.74 14.84 14.38
ROE: 113.57 16.34 16.07

AbbVie's rheumatoid arthritis drug succeeds in late-stage study

Abbvie Inc said on Tuesday its experimental drug met the main goal of halting progression of moderate-to-severe rheumatoid arthritis in a late-stage trial.

05 Jun 2018

UPDATE 1-AbbVie's rheumatoid arthritis drug succeeds in late-stage study

June 5 Abbvie Inc said on Tuesday its experimental drug met the main goal of halting progression of moderate-to-severe rheumatoid arthritis in a late-stage trial.

05 Jun 2018

AbbVie's rheumatoid arthritis drug succeeds in late-stage study

June 5 Abbvie Inc said on Tuesday its experimental drug upadacitinib met the main goals of a late-stage study in patients with moderate-to-severe rheumatoid arthritis.

05 Jun 2018

Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod

ZURICH Novartis's generics unit on Friday won a European panel's recommendation for its biosimilar version of AbbVie's Humira as the Swiss drugmaker aims to take a bite out of sales of one of the world's best-selling medicines.

01 Jun 2018

Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod

ZURICH, June 1 Novartis's generics unit on Friday won a European panel's recommendation for its biosimilar version of AbbVie's Humira as the Swiss drugmaker aims to take a bite out of sales of one of the world's best-selling medicines.

01 Jun 2018

Goldman's Waldron says U.S. tax reform boosts shareholder activism

LOS ANGELES U.S. companies with more cash on their balance sheets thanks to tax reform are coming under greater scrutiny from activist investors, a top Goldman Sachs Group Inc investment banker said this week.

03 May 2018

REFILE-Goldman's Waldron says U.S. tax reform boosts shareholder activism

LOS ANGELES, May 2 U.S. companies with more cash on their balance sheets thanks to tax reform are coming under greater scrutiny from activist investors, a top Goldman Sachs Group Inc investment banker said this week.

03 May 2018

BRIEF-Abbvie Estimates Complete Blackout Could Begin As Soon As 4 P.M NY Time on May 23

* ABBVIE - ESTIMATE THAT COMPLETE BLACKOUT COULD BEGIN AS SOON AS 4 P.M., NEW YORK CITY TIME ON MAY 23, 2018 AND COULD EXTEND THROUGH JUNE 13, 2018 Further company coverage:

02 May 2018

BRIEF-Abbvie Submits Marketing Authorization Application To EMA For Investigational Treatment Risankizumab For Moderate To Severe Plaque Psoriasis

* ABBVIE SUBMITS MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR INVESTIGATIONAL TREATMENT RISANKIZUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS

01 May 2018

BRIEF-AbbVie Commences Self-Tender Offer For Up To $7.5 Bln Of Its Common Stock

* ABBVIE COMMENCES SELF-TENDER OFFER FOR UP TO $7.5 BILLION OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

01 May 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $122.61 --
Pfizer Inc. (PFE.N) $36.36 +0.20
Novartis AG (NOVN.S) CHF75.60 +0.10
Merck & Co., Inc. (MRK.N) $62.03 --
Roche Holding Ltd. (ROG.S) CHF210.95 -0.90
Roche Holding Ltd. (RO.S) CHF215.40 +0.40
Abbott Laboratories (ABT.N) $62.91 -0.05
Eli Lilly And Co (LLY.N) $86.88 +0.53
Sanofi SA (SASY.PA) €67.64 -1.04

Earnings vs. Estimates